Project Farma’s Anshul Mangal sat down with Pharmaceutical Technology to discuss the impact of the BIOSECURE Act on pharmaceutical companies and outline steps both large pharma and small-to-mid-sized biotechs can take to mitigate its impact. Click here to read more: https://hubs.ly/Q02JdZkk0 #BIOSECUREACT#CDMO#WuXi#patientfocused
About us
Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.
- Website
-
http://www.precisionformedicine.com
External link for Precision For Medicine
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Bethesda, MD
- Type
- Privately Held
- Specialties
- Global Clinical Trial Services, Specialty Lab Services, Translational Science, Clinical Data Management, Biostatistics, Biomarker Strategies, Sample Sourcing and Storage, Immune Monitoring, IVD Development, CDx Development, Market Access, IVD CRO, Regulatory Strategy and Submission, and Contract Research Organization
Locations
-
Primary
2 Bethesda Metro Center
Suite 850
Bethesda, MD 20814, US
-
8425 Progress Drive
Fredrick, MD 21701, US
-
55 Cambridge Parkway
Ste 300E
Cambridge, MA 02142, US
Employees at Precision For Medicine
Updates
-
We are thrilled to announce that Renise Blythe has joined our team as Vice President, Global Pharmacovigilance and Drug Safety. With over 20 years of extensive experience in pharmacovigilance, drug safety, regulatory affairs, and risk management, Renise brings a wealth of knowledge and a proven track record of success. Her background in oncology, critical care, and women’s health, combined with her expertise in both CRO and pharmaceutical environments, will be invaluable to our mission. Renise’s dedication to patient safety, compliance, and collaboration aligns perfectly with our core values. Her passion for advancing research and improving patient outcomes will undoubtedly make a significant impact as we continue to drive innovation in the healthcare industry. Welcome to the team, Renise!
-
-
Precision For Medicine reposted this
In this issue of our Precision Manufacturing newsletter, we outline the key considerations for acquiring a cell and gene therapy biotech. From evaluating R&D pipelines to mitigating risks, ensuring leadership synergy, and fortifying IP foundations, our experts provide a blueprint for navigating this complex and competitive terrain. Click below to read more and subscribe today! #GeneTherapy #CellTherapy #CGT #Growth #IntellectualProperty
-
Precision has millions of available banked biospecimens, both healthy and disease-state, ready to meet the needs of any diagnostic development program. Visit our booth at ADLM to inquire about our specific inventory. #ADLM24 #ADLM2024 #biospecimens
-
-
Create better tomorrows ... remotely. Seeking European candidates. Senior Regulatory Manager: https://hubs.ly/Q02J0S270 Director, Operational Strategy: https://hubs.ly/Q02J0WDq0 #pharmajobs #clinicalresearch #oncology #womeninscience
-
-
109 countries are hosting or planning rare oncology trials. Explore the indications, phases, geographies and more in this data deep-dive. https://hubs.ly/Q02HSvcl0 #clinicalresearch #oncology #rarediseases
-
-
FDA ODAC Vote Today: Implications and Insights Watch Chief Medical Officer and former FDA oncology division director, Dr. Harpreet Singh, MD, as she quickly breaks down the upcoming FDA Oncologic Drugs Advisory Committee (ODAC) vote and its potential impact on drug development. Key points covered: • Background on today's ODAC vote on AstraZeneca's lung cancer trial • FDA's concerns about trial design and patient over-treatment • Implications for future perioperative trials in oncology Dr. Singh’s insights: • The importance of trial design in proving treatment efficacy • How this vote could affect drug developers across multiple cancer types • Potential changes in FDA requirements for perioperative trials See what this could mean for patients, providers, and the future of cancer drug development. 💬 What are your thoughts on the FDA's stance? How might this impact your work in oncology drug development? Follow Dr. Singh for more FDA insights and expert analysis #fdainsights #OncologyTrials #DrugDevelopment #ClinicalTrialDesign
-
Seamless clinical trials combine two phases into one dynamic study design. It’s something we’ve done 46 times in the past 3 years—here’s what we’ve learned...https://hubs.ly/Q02HM_zT0 #oncology #clinicaltrials #drugdevelopment
-
-
The FDA’s initiative to widen the scope of participation in oncology trials is a step toward bridging the gap between clinical research and the diverse spectrum of patients it aims to serve. By redefining who gets to participate in these trials, this improves access to cutting-edge treatments and ensures that the findings are more applicable to those they’re meant to help. Learn more here: https://hubs.ly/Q02HB_XK0 #oncology #clinicaltrials #fda
-
-
Our Precision team in Frederick, MD had the honor of sponsoring a 5K run organized by Girls on the Run, an organization dedicated to inspiring girls to be joyful, healthy, and confident through running. Our team was on hand to cheer the participants, distribute refreshments, and join in the festivities. Click here to learn more: https://hubs.ly/Q02HltH20 #patientfocused #peoplefirst
-